Friday 6 November 2026
Export ADMA’s income statement to Excel — free account
ADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
13.02
0.19
−1.44%
Follow ADMA
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 4 | 5 |
+8 more TTM periods Free account |
| 41.95% | 41.90% | 43.30% | 35.56% | ||
| 28.04% | 27.19% | 28.13% | 26.40% | ||
ROIC |
48.02% | 29.78% | 29.70% | 25.69% | |
Return on Tangible Assets |
33.33% | 32.55% | 32.90% | 31.80% | |
Average Days of Receivables |
118.98 | 98.49 | 97.26 | 113.35 | |
Free Cash Flow per Share |
0.63 | 0.51 | 0.48 | 0.12 | |
Free Cash Flow |
140.48 | 116.22 | 112.55 | 27.51 | |
Capital Expenditures |
(0.31) | (20.50) | (15.77) | (22.89) | |
| Other line items | |||||
Cash ROIC |
24.95% | 15.64% | 15.45% | 4.29% | |
Accounts Receivable Turnover |
3.38 | 4.13 | 4.33 | 4.90 | |
Accounts Payable Turnover |
5.48 | 5.88 | 9.60 | 10.17 | |
Inventory Turnover |
0.71 | 0.84 | 1.00 | 1.15 | |
Average Days of Payables |
79.66 | 64.04 | 37.94 | 37.81 | |
Days of Inventory on Hand |
594.46 | 483.11 | 410.57 | 346.63 | |
Tax Rate |
(0.22) | (0.22) | (0.20) | (0.20) | |
Research and Development Expense of Revenue |
2.79% | 2.25% | 1.28% | 0.93% | |
Selling, General and Administrative Expense of Revenue |
19.94% | 19.28% | 18.48% | 17.95% | |
Share Based Compensation of Revenue |
4.63% | 4.47% | 4.26% | 3.93% | |
Interest Coverage |
22.80 | 25.44 | 29.69 | 26.93 | |
Operating CF/Net income |
0.77 | 0.81 | 0.78 | 0.34 | |
Depreciation/Fixed assets |
0.00 | 0.12 | 0.13 | 0.13 | |
Capex/Depreciation |
0.00 | (2.47) | (1.85) | (2.64) | |
Revenue per Share |
2.32 | 2.24 | 2.16 | 2.14 | |
Operating CF per Share |
0.63 | 0.60 | 0.54 | 0.21 | |
Capex per Share |
0.00 | (0.09) | (0.07) | (0.10) | |
Capex to Sales |
0.00 | 0.04 | 0.03 | 0.04 |
Columns are period end dates · fundamentals updated 4 Nov 2026